MayoComplete Comprehensive Sarcoma Panel, Next-Generation Sequencing, Tumor
Use
This test is primarily used for identifying mutations and gene fusions that assist in diagnosing specific soft tissue and bone tumors (sarcoma). It also serves a secondary function of identifying variants with therapeutic or prognostic significance. The assessment of microsatellite instability informs immunotherapy decisions and is clinically actionable for determining the efficacy of such treatments in solid tumors.
Special Instructions
A pathology report containing the patient's name, block number, tissue collection date, source of the tissue, and diagnosis must accompany the specimen for testing. If the specimen is insufficient to perform all testing components, a reflex test will be added based on prioritization preferences indicated on the paperwork. Unused unstained slides will not be returned. An Oncology Test Request Form (T729) must be completed if not ordering electronically.
Limitations
This test cannot distinguish between somatic and germline alterations. RNA is labile, and its degradation may affect results; preservation post-collection is critical. Variants or fusions of uncertain significance may be reported. A negative result does not exclude the presence of variants below detection limits. Analytical sensitivity is 5% mutant allele frequency with a minimum 500x coverage in samples with ≥20% tumor content. For gene fusions, coverage must reach 5 unique variant molecules with ≥10% tumor content. Limitations include not detecting multi-exon deletions, larger genomic copy number variants, or promoter methylation.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 95124-4
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 80398-1
- 85069-3
- 62364-5
- 18771-6
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
formalin-fixed, paraffin-embedded tissue block or slides
Collection Instructions
Submit a tissue block or slides with sufficient tumor tissue and 20% or more tumor nuclei.
Causes for Rejection
Improper collection or handling, insufficient tumor nuclei, or degradation of RNA.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient (preferred) |